ro 22-9194 has been researched along with thromboxane a2 in 1 studies
| Studies (ro 22-9194) | Trials (ro 22-9194) | Recent Studies (post-2010) (ro 22-9194) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 11 | 0 | 2 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanazawa, T; Kinukawa, M; Maruyama, K; Miyagi, M; Miyata, H; Murakami, M; Ujiie, A | 1 |
1 other study(ies) available for ro 22-9194 and thromboxane a2
| Article | Year |
|---|---|
Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cyclooxygenase Inhibitors; Disopyramide; Dogs; Enzyme Inhibitors; Female; Humans; Male; Methacrylates; Mexiletine; Myocardial Ischemia; Myocardial Reperfusion Injury; Platelet Aggregation; Pyridines; Thromboxane A2; Thromboxane-A Synthase | 1996 |